Biotech RadarJobs updated

COMPANY

Reviva Pharmaceuticals

HQ: Cupertino, CA source · revivapharma.com ↗ · West Coast

Clinical Phase 3

Reviva’s current pipeline focuses on the central nervous system (CNS), inflammatory and cardiometabolic diseases. From company website Source · Oct 12, 2026

Keywords: CNS ; inflammatory neurology metabolic respiratory metabolic diseases schizophrenia bipolar disorder Acute Schizophrenia Schizoaffective Disorder RP5063 Brilaroxazine

Location: Cupertino, CA · source · Oct 14, 2026

Profile checked Oct 10, 2026

$47.0MRaised (2 yrs)2Trials (company is sponsor)

Timeline

  1. Raise Follow-on offering: $10M (total, as published), announced Mar 23, 2026. Source: company release on GlobeNewswire. source ↗
  2. Raise Follow-on offering: $9M (total, as published), announced Sep 18, 2025. Source: SEC filing. source ↗
  3. Raise Follow-on offering: $10M (total, as published), announced Jun 26, 2025. Source: SEC filing. source ↗
  4. Raise Follow-on offering: $18M (total, as published), announced Dec 16, 2024. Source: SEC filing. source ↗
  5. Trial start Phase 3: Safety and Efficacy of Brilaroxazine (RP5063) in Schizophrenia source ↗
  6. Trial start Phase 2: RP5063 in Subjects With Schizophrenia or Schizoaffective Disorder source ↗

Funding

Raised: $47.0M. Last 2 years.

Clinical trials (lead sponsor) 2

RecordTitlePhaseStatusStartPrimary completion
NCT01490086RP5063 in Subjects With Schizophrenia or Schizoaffective DisorderPhase 2Completed2011-122013-03 (actual)
NCT05184335Safety and Efficacy of Brilaroxazine (RP5063) in SchizophreniaPhase 3RecruitingJan 24, 20222025-02 (estimated)
Feedback